Fairvalue-Calculator Fairvalue-Calculator
EN DE

Jiangxi ZhengBang Technology Co (002157) Fair Value & Analysis

Consumer Defensive · CN · Market cap 28.6B CNY

Price¥2.92
Fair Value¥1.54
Upside-47.3%
Quality87/100
Evidence: Low Range ¥1.20 – ¥1.87

Analysis

Jiangxi ZhengBang Technology Co (002157) currently trades at ¥2.92, while our model-based Fair Value estimate is ¥1.54 — implying the stock looks roughly 47.3% overvalued today. We read business quality at 87/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Jiangxi ZhengBang Technology Co., Ltd., together with its subsidiaries, engages in the agriculture business in China and internationally. It operates through three segments: Feed, Pig Farming, and Veterinary Drugs. The company offers pig, poultry, aquatic, ruminant, and concentrated feed products; and fattened pigs and piglets for slaughtering, deep processing, and breeding. It also researches, develops, produces, and sells veterinary drugs, mixed feed additives, and premixed feed additives. In addition, the company is involved in aquaculture; trading; financial services; project investment; and bond issuance. The company was founded in 1996 and is headquartered in Nanchang, China.

Open the full interactive analysis →

Similar stocks

Archer-Daniels-Midland Company (ADM) -53% MHP SE (MHPC) -88% Muyuan Foods Group (002714) +40% Bunge Global SA (BG) -31% Tyson Foods, Inc (TSN) -17% Wens Foodstuff Group (300498) -3%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.